The Effects of Long-Term Using Once-A-Month Injectable Contraceptive Norethisterone Enanthate/ Estradiol Valerate on Coagulation in the Chinese

Summary

Sixty-four Chinese women were studied for the effects of injecting once-a-month contraceptive norethisterone enanthate/ estradiol valerate between 2 to 4 1/2 years on certain coagulation and fibrinolytic parameters, and 59 women not receiving any steroidal contraception were controls. In both groups there was no significant change in PT, fibrinogen, factor X activity, AT III antigen, AT III activity and fibrinolytic activity expressed by euglobulin lysis time. There was no significant difference in mean levels of factor VIIIR:Ag between the two groups, although a sub-group women in treatment group had higher than accepted levels of factor VIIIR:Ag.

• References

• 1 Jordan WM. Pulmonary embolism. Lancet 1961; 2: 1146
• 2 Grant EC G. Venous effects of oral contraceptives. Br Med J 1969; iv: 73
• 3 Inman WH W, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; ii: 203
• 4 Royal College of General Practitioners. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; i: 624
• 5 Mead TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-pg oestrogen preparations. Br Med J 1980; 282: 1157
• 6 Sang GW. Presentation at the National Symposium on Long-Acting Agents, Hangzhou, People’s Republic of China. 14-15 January 1983
• 7 Dacie JV, Lewis SM. Practical Haematology, 6th edition. Churchill Livingstone 1984; 216
• 8 Xu FY. Hemorrhagic disease. Shanghai Publishing House of Science & Technology, China 1979; 337-338
• 9 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 43
• 10 Aurell L, Friberger P, Karlsson G, Claeson G. A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb Res 1977; 11: 595
• 11 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrates. Thromb Res 1977; 11: 549
• 12 Copley AL, Miewiarowski S, Marechal J. A micromethod of euglobulin fibrinolysis in plasma of human subjects and small laboratory animals. J Lab Clin Med 1959; 53: 468
• 13 Poller L. Oral contraceptive, blood clotting and thrombosis. Br Med Bull 1978; 34: 151
• 14 Notelovize M, Kitchens C, Coone L. et al. Low-dose oral contraceptive usage and coagulation. Am J Obstet Gynecol 1981; 141: 71
• 15 Mead TW, Haines AP, North WR S. et al. Haemostatic, lipid, and blood pressure profiles of women on oral contraceptives containing 50 Μg or 30Μg oestrogen. Lancet 1977; 2: 948
• 16 Nagasawa H, Hotta Y, Takara N. et al. Inhibitory effects of oestrogens on antithrombin III. Thromb Diath Haemorrh 1975; 34: 345
• 17 Chetkowski RJ, Meldrum DR, Steingold KA. et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620
• 18 Christe M, Delley A, Marber GA. et al. Fibrinogen, factor VIII related antigen, antithrombin III and a2-antiplasmin in peripheral arterial disease. Thromb Haemostas 1984; 52: 240-242
• 19 Yu GR. et al. Clinical significance of plasma VIIIR:Ag and patients with a coronary disease. Chin J Cardio 1985; 13: 178
• 20 Zhang TR, Wang SD, Yu JH. et al. The preparation of antiserum of factor VIII related antigen. Chin J Haematol 1980; 1: 193